Julia Lainster

The escalating complexity and cost of pharmacy benefits have placed unprecedented pressure on health plans, forcing many to operate within the rigid confines of outdated, legacy systems that hinder both fiscal responsibility and member satisfaction. In this highly competitive landscape, the pursuit

Amidst a technological gold rush driven by generative artificial intelligence, healthcare payers are navigating a complex landscape where the pressure to innovate confronts the non-negotiable demand for absolute accuracy and compliance. Unlike other industries that can afford to experiment more

Retirement planning often focuses on accumulating a substantial nest egg, but a critical and frequently underestimated factor can unravel even the most carefully constructed financial strategies: the relentless rise of healthcare costs. While gross income and Social Security benefits provide a

In an increasingly challenging pharmaceutical landscape, where the price of a new therapy is scrutinized with unprecedented intensity, simply proving a drug is safe and effective is no longer sufficient. Life sciences companies now face the monumental task of demonstrating clear clinical and

Every groundbreaking medical treatment and public health policy that shapes modern life rests upon a complex and often invisible framework of mathematical precision and analytical rigor. Behind the celebrated discoveries of new drugs and the development of life-saving vaccines lies a discipline

A critical U.S. federal funding package that is essential for extending modern healthcare services now finds itself ensnared in a high-stakes political battle over immigration enforcement, placing the future of virtual patient care in jeopardy. The legislation at the heart of the matter, the

In a move that reverberates across the global pharmaceutical landscape, AstraZeneca has committed to a monumental $15 billion long-term investment in China, signaling a profound strategic alignment with the nation's rapidly ascending role as a biopharmaceutical powerhouse. This massive financial

The Food and Drug Administration's Center for Devices and Radiological Health (CDRH) has presented a picture of remarkable operational stability in its 2025 annual report, successfully maintaining its core device review functions despite navigating significant internal pressures and substantial

Faced with a cancer mortality rate that is 5.4% higher than the European Union average and the third highest in Western Europe, leaders from across the island of Ireland have initiated a landmark strategy to confront a public health crisis of escalating proportions. Projections indicating that new

A recent state audit has unearthed a staggering financial blunder within a single New Jersey school district, revealing that nearly fifty million dollars in potential savings on employee health insurance were completely squandered over just four years. This incident in Perth Amboy is not an